Ignite Creation Date:
2024-05-05 @ 5:05 PM
Last Modification Date:
2024-10-26 @ 9:28 AM
Study NCT ID:
NCT00385710
Status:
COMPLETED
Last Update Posted:
2012-11-04
First Post:
2006-10-10
Brief Title:
Trial of Valproic Acid in Patients With Progressive Supranuclear Palsy Depakine
Sponsor:
Nantes University Hospital
Organization:
Nantes University Hospital
Study Overview
Official Title:
Randomized Placebo-controlled Trial of Valproic Acid in Patients With Progressive Supranuclear Palsy
Status:
COMPLETED
Status Verified Date:
2011-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Progressive Supranuclear Palsy PSP is a relentlessly progressive neurodegenerative disorder clinically characterized by parkinsonism with prominent axial involvement and postural instability bulbar symptoms supranuclear ophthalmoplegia and executive dysfunction Abnormal neuronal and glial tau aggregations affecting the basal ganglia and selective brainstem structures result in dysfunction of the five frontosubcortical circuits and brainstem functions There is no effective treatment for PSP One of the key feature in the aggregation of tau is its phosphorylation by kinases such as glycogen synthase kinase 3b GSK3b Recent reports have shown that valproic acid was able to inhibit the activity of GSK3b and could exert a neuroprotective effect through this inhibition The investigators thus decided to conduct this controlled study to assess the putative neuroprotective effects in patients with PSP
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None